Stock of the Day - March 21, 2023

ACADIA Pharmaceuticals (ACAD)

$19.71

+$0.46 (+2.4%)

Market Cap: $3.32B

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Trend

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is being influenced by sharply reduced analyst expectations and renewed discussion of the company’s growth prospects. The UBS downgrade and target-price cut appear to be the main reasons for recent weakness, although the stock retains potential upside based on the broader analyst consensus.

Brokerages maintain an average price target of $31.34, well above recent trading levels, suggesting analysts collectively see substantial recovery potential for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals Inc. Stock Has Average Target Price of $31.34 According to Brokerages
Nuplazid and Daybue remain important growth drivers, supported by demand growth, potential new formulations and European expansion. These opportunities could help offset increasing competition and strengthen ACADIA’s longer-term revenue outlook. Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACADIA shares reached a new 52-week low near $19, highlighting continued technical pressure and investor caution following the recent selloff. Acadia Pharmaceuticals stock hits 52-week low
UBS downgraded ACADIA Pharmaceuticals from Buy to Neutral and slashed its price target from $49 to $23. The move signals reduced confidence in the stock’s near-term upside and triggered selling pressure. ACADIA Pharmaceuticals Shares Fall After UBS Downgrade
Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. Although no conclusions or allegations have been established, the announcement adds legal and reputational uncertainty. Pomerantz Law Firm Investor Alert

← Previous Stock of the Day Next Stock of the Day →

ACADIA Pharmaceuticals (ACAD)

About ACADIA Pharmaceuticals

Today's Trend

Recent News